Bio.News: BIO 2024: Can data improve clinical trial diversity?
“One of the things that we’ve noticed, not just in the pandemic, is this problem of missing race and ethnicity information,” explained Carla Rodriguez-Watson, Ph.D., MPH, Director of Research at the Reagan-Udall Foundation for the FDA. “If you do not have this information, where patients are being seen, where their information is being collected, then we have a limited view into what that population distribution of disease is.”